Summary The use of a somatostatin analogue has greatly facilitated the treatment of patients with the midgut carcinoid syndrome. Clinical studies have shown that SMS reduces the peripheral levels of tumour-produced serotonin (5-HT) and tachykinins, e.g. neuropeptide K (NPK), basally and after pentagastrin provocation. Some studies have indicated an inhibitory effect of SMS on tumour cell growth as well. In the present study we Moattari, 1989; Gorden et al., 1989) . In clinical studies the somatostatin analogue has been shown to reduce the levels of tumour-produced serotonin (5-HT) and tachykinins, e.g. neuropeptide K (NPK), in peripheral blood under basal conditions and after pentagastrin (PG) provocation (Ahlmann et al., 1988a; Oberg et al., 1989) . Hemodynamic studies have demonstrated that octreotide rapidly stabilises arterial blood pressure during carcinoid crisis despite high circulating levels of 5-HT, indicating a peripheral site of action as well (Kvols et al., 1985; Ahlman et al., 1988a) . Using a model with intraocular heterotransplants of human midgut carcinoid tumours to immunosuppressed rats we have previously demonstrated a significant reduction of the P-adrenoceptor mediated release of 5-HT from these tumours after systemic treatment of the host animals with octreotide (Ahlund et al., 1989b) . However, in those studies the effect of the drug may theoretically have been conveyed via receptors on tumour vessels and/or on the tumour cell surface. In order to investigate the effects of the somatostatin analogue on isolated tumour cells, we have studied growth and secretion of 5-HT and NPK from cultured human midgut carcinoid tumour cells subjected to octreotide treatment. The biochemical response to treatment with octreotide, studied by urinary levels of 5-hydroxyindoleacetic acid (5-HIAA) and by levels of 5-HT in peripheral whole blood during PG provocation, were also monitored in the clinical situation.
The use of a somatostatin analogue (octreotide, SandostatinR, has greatly facilitated the clinical treatment of patients with the midgut carcinoid syndrome (Kvols et al., 1986; Vinik & Moattari, 1989; Gorden et al., 1989) . In clinical studies the somatostatin analogue has been shown to reduce the levels of tumour-produced serotonin (5-HT) and tachykinins, e.g. neuropeptide K (NPK), in peripheral blood under basal conditions and after pentagastrin (PG) provocation (Ahlmann et al., 1988a; Oberg et al., 1989) . Hemodynamic studies have demonstrated that octreotide rapidly stabilises arterial blood pressure during carcinoid crisis despite high circulating levels of 5-HT, indicating a peripheral site of action as well (Kvols et al., 1985; Ahlman et al., 1988a) . Using a model with intraocular heterotransplants of human midgut carcinoid tumours to immunosuppressed rats we have previously demonstrated a significant reduction of the P-adrenoceptor mediated release of 5-HT from these tumours after systemic treatment of the host animals with octreotide (Ahlund et al., 1989b) . However, in those studies the effect of the drug may theoretically have been conveyed via receptors on tumour vessels and/or on the tumour cell surface. In order to investigate the effects of the somatostatin analogue on isolated tumour cells, we have studied growth and secretion of 5-HT and NPK from cultured human midgut carcinoid tumour cells subjected to octreotide treatment. The biochemical response to treatment with octreotide, studied by urinary levels of 5-hydroxyindoleacetic acid (5-HIAA) and by levels of 5-HT in peripheral whole blood during PG provocation, were also monitored in the clinical situation.
Material and methods
Clinical provocation with pentagastrin A provocation test using PG (0.6 jg kg-' i.v.) was used Oberg et al., 1989) . The levels of 5-HT in peripheral whole blood were determined under basal conditions and 1, 3, and 5 min after injection of PG. The provoked release of 5-HT was expressed as the ratio between the highest level after injection and the mean basal level of 5-HT (peak/basal ratio ref. < 1.40). The urinary 5-HIAA levels at referral were 300 tsmol 24 h-' and the peak/basal ratio of 5-HT levels in peripheral whole blood at PG provocation were 1.50 (basal level 590 ng ml-'). After treatment with SMS (100 fig x 2 fig ml-' ), insulin (5 ILg ml-'), and streptomycin (200 gtg ml-'), and incubated at 37°C in a 90%-humidified atmosphere with 20% 02 and 5% CO2. Tumour cells were grown for 9-13 weeks and media were changed every 3-4 days. Samples of culture media were withdrawn regularly and assayed for 5-HT and NPK-like immunoreactivity (NPK-LI).
Determination of 5-HT Aliquots (10 yl) of culture medium, or peripheral blood after hemolysis and protein precipitation (cf. Ahlman et al., 1985) , were injected onto the column of an HPLC system with electrochemical detection to determine 5-HT. Standard curves were made by injecting standard solutions of 5-HT (5-hydroxytryptamine-creatininesulfate, Sigma) in 10 JLl of 0.1 M perchloric acid (Ponzio & Jonsson, 1978) .
Assay of NPK-LI Tachykinins other than substance P were determined by radioimmunoassay using antiserum K12 as previously described (Theodorsson-Norheim et al., 1985) . Using the crossreactivity to neurokinin A (NKA) as the 100% reference, the crossreactivity to kassinin was 84%, eledoisin 30%, NKB 26% and NPK 61%. The major immunoreactive component measured by antiserum K12 in media from cultured carcinoid cells is NPK, and NPK-LI will, therefore, subsequently be used to denote the immunoreactive material. In plasma and extracts of tumour tissue antiserum K12 detects NKA, NKA-sulphoxide, NKA (3-10) and NKA (4-10) and an eledoisin-like peptide (Theodorsson-Norheim et al., 1985; Norheim et al., 1987) .
Assay of DNA Cultured tumour cells were sonicated in Tris-LiCl and stored at -20°C until assay. The fluorochrome Hoechst 33258 was added to the samples and DNA-concentrations were measured spectrophotometrically (Labarca & Paigen, 1980) .
Statistical methods
Given values are mean ± s.e.m. and for significance testing we have used unpaired t-test, two tailed.
Experimental protocol Cell cultures of the four tumours (cases I-IV) were incubated with SMS 201-995 (Sandoz, Basel, Switzerland) after 4-6 weeks of primary culture. Culture media were changed every 3-4 days and replaced with fresh media containing SMS. During experiments medium concentrations of 5-HT and/or NPK-LI were followed at regular intervals and compared with control cultures in standard medium.
Six experimental protocols were used:
Protocol I Tumour cell cultures (case I) were incubated with two different concentrations of SMS (10°-M or 10-8 M) during a 2-week period and then allowed to recover for 3 weeks ( Figure 2 ).
Protocol 2 Tumour cell cultures (case II) were incubated with SMS 10"M for 2 weeks, followed by SMS 10-9M for 2 weeks, and finally by SMS 10-8 M for another 2 weeks. Tumour cells were then allowed to recover for 1-2 weeks ( Figure 3 ). Incubation of tumour cells with two different concentrations of SMS (10-10 M or 10-8 M) for a 2-week period (protocol 1) caused a marked decrease in the 5-HT levels in culture media. Treatment with SMS 108 M, but not 10-ioM, also caused a significant (P <0.05) reduction in the levels of NPK-LI. Two weeks after cessation of SMS treatment the levels of 5-HT and NPK-LI in culture media were similar to those in untreated controls (Figure 2a,b) .
Tumour cells, incubated with increasing concentrations of SMS (10-'0 M-I0-I M) during three successive 2-week periods (protocol 2), maintained the concentrations of 5-HT and NPK-LI at a low level compared with non-treated controls. Even 2 weeks after the test period tumour cell culture media had significantly lower levels of 5-HT than controls, while the levels of NPK-LI did not differ. At the end of the observation period the 5-HT levels of controls were still high while the NPK-LI levels were much reduced (Figure 3a,b) . Tumour cells incubated with SMS 10-M over 5 weeks (protocol 3) showed much lower 5-HT levels than tumour cells incubated with the SMS vehicle alone during the entire stimulation period. Both groups showed a cyclic variation (with 15 day cycles) of 5-HT levels in the media, as previously observed in long-term cultures (Ahlund et al., 1989a) . No signs of densensitisation to SMS were noted (Figure 4) .
Incubation of tumour cell cultures with SMS (10-10M or 10-8 M) during 2 weeks (protocol 4) resulted in significantly decreased 5-HT levels compared with untreated controls. However, the DNA contents were very similar in treated and non-treated groups (Table I) . Cells from the same tumour were seeded at two different cell densities. A constant, but low, number of fibroblasts were demonstrated in all cultures. The ratio of 5-HT concentration in culture media over DNA contents of the two types of cultures did not differ. However, this ratio was clearly suppressed by SMS treatment (Table I) . Tumour cell cultures from case III were also treated with SMS (10-8 M) during 4 days (protocol 5). Even this short treatment significantly reduced the media levels of 5-HT, as well as the intracellular levels of 5-HT, detected after sonication of the cultures. The DNA contents in these experiments were also similar in treated and non-treated cultures ( Figure  5a ,b,c).
Influence of SMS 201-995 on P-adrenoceptor induced release of 5-HT Tumour cell cultures from case III were stimulated with IP (10-6 M) 1 or 4 days after change of media. In both situations a pronounced release of 5-HT was demonstrated. However, the cells studied after 4 days had significantly higher media levels of 5-HT. Pretreatment with SMS 10-8 M for 4 days kept the basal 5-HT concentration in the media at a similar level as at onset of the experiment. The release of 5-HT upon IP stimulation (10-6 M) was, however, similar to untreated controls (Figure 6a ). Tumour cell cultures from case IV (protocol 5) also showed a pronounced release of 5-HT with IP (10-6 M) after pretreatment with SMS I0O-M for 1 or 4 h. Sole incubation with SMS 10-8 M during these time periods had no effect on the 5-HT levels ( Figure 6b ).
Discussion
Somatostatin was originally characterised as a peptide hormone (14 amino acids) inhibiting the release of growth hormone in the hypothalamus (Brazeau et al., 1973) . How-I A ever, somatostatin occurs widely in the CNS and in the gastro-enteric-pancreatic endocrine system. it has been ascribed a role as physiological regulator of secretion, e.g. it inhibits the secretion of pancreatic and gut hormones and exocrine secretion as well (Reichlin, 1983) . Bauer et al. (1982) synthesised an analogue (SMS 201-995) of the conformationally stable part of somatostatin (eight amino acids), which was highly resistant to degradation and selective in its inhibition of growth hormone secretion. This compound has become a most valuable medical adjunct in the treatment of several pancreatic and gut endocrine tumours due to its suppression of hormone overproduction Lamberts et al., 1990) .
In the present study we have obtained evidence for a direct effect of SMS on human midgut carcinoid tumours in culture. In all four tumours studied SMS reduced the media levels of both 5-HT and NPK-LI in cultures of human midgut carcinoid tumour cells within 4 days. The reduction appeared to be stable during the period of study and was similar at the two concentrations tested. In one experimental protocol (2) control tumour cells were observed over 90 days. The low media levels of NPK-LI at the end of this period contrasted with well maintained levels of 5-HT. This finding might indicate that the synthesis and secretion of peptides and amines have different control mechanisms. Such differences are evident in the response to stimulation with Padrenoceptor agonists, i.e. 5-HT being released without changes of tachykinin levels (Ahlman et al., 1988b) . In these experiments pretreatment of tumour cells with SMS did not significantly inhibit the P-adrenoceptor induced release of 5-HT, tested after pretreatment up to 4 days. This is in contrast to the clinical situation, where treatment with SMS for 4 days reducts both the basal and provoked levels of 5-HT (Ahlman et al., 1988a) . Case I in this series had decreased levels of both urinary 5-HIAA (63%) and basal 5-HT in peripheral blood (63%) accompanied by an extinguished release reaction to PG after 4 weeks of treatment with SMS. Case II had decreased 5-HIAA levels (23%) and no release reaction upon PG provocation after 3 months of treatment. Both these patients underwent similar treatment with surgical debulking, liver ischemia and continuous SMS treatment leading to a long-lasting state of biochemical normalisation. Sole treatment with SMS in the carcinoid syndrome had not been reported to reduce 5-HIAA levels into the normal range of any patients (Gorden et al., 1989) . Case II and IV underwent uneventful major surgical procedures under protection with SMS according to a previously reported program (Ahlman et al., 1988a) resulting in total remission of disease radiologically as well as biochemically.
PG has previously been shown not to cause release of 5-HT from human midgut carcinoid tumour cells in vitro (Nilsson et al., 1985) . In vivo there is strong experimental evidence that PG acts via an indirect mechanism causing release of catecholamines from the adrenals, in turn activating P-adrenoceptors located on enterochromaffin cells (or carcinoid tumour cells) (Gronstad et al., 1987) . Previous studies using autoradiography and in vitro binding assay have shown saturable and high affinity receptors with specificity for somatostatin on several different human endocrine tumours (Reubi et al., 1987a,b; Lamberts et al., 1990) . Our findings indicate that SMS, presumably bound to receptors on the midgut carcinoid tumour cells, inhibits the secretion of tumour products via a second messenger system different from the one mediating the P-adrenoceptor stimulated release of 5-HT. The discrepancy between the blocked PG response seen clinically and the unaffected release of 5-HT at Padrenoceptor stimulation seen in vitro (e.g. Case III) may indicate that SMS also reduces the PG induced release of catecholamines from the adrenal medulla. Alternatively, the ,B-adrenoceptor mechanism may operate via a modified tumour receptor, since the IP-induced release from tumour cell cultures cannot be blocked by P-adrenoceptor antagonists (Ahlman et al., 1988b) . However, immunocytochemically, midgut carcinoid tumour cells display a positive reaction with an antiserum directed against the ,B-adrenoceptor protein (Wangberg et al., 1990) . The decreased intracellular levels of 5-HT after short-term (4 days) treatment with SMS, in combination with unchanged DNA contents, may indicate a suppressed synthesis of 5-HT as well. In the present study we have confirmed our previous observations (Ahlund et al., 1989a ) on a cyclicity of 5-HT secretion from cultured carcinoid tumour cells (Figures 2 and 4) . Parallel changes in the secretion of NPK-LI were also observed ( Figure 2 ) and SMS treatment did not abolish the cyclicity. Since the assays were done in separate laboratories and at different times a technical error is less likely. Periodic induction of enzyme systems by local production of certain factors cannot be excluded.
Naturally occurring somatostatin appears to be an endogenous growth inhibitor, which delays the separation of centrosomes indicative of the GI phase (Mascardo & Sherline, 1982) . With the recent development of potent somatostatin analogues a certain interest has been focused on the inhibition of growth of experimental tumours in animal models i.e. rat chondrosarcomas (Reubi, 1985) , mice osteosarcoma (Cai et al., 1986) , acinar pancreatic carcinoma in rats (Redding & Schally, 1984) , prolactin-secreting pituitary carcinoma in rats (Lamberts et al., 1986) , and mammary, prostate and ductal pancreatic carcinomas in rats (Cai et al., 1986) . Several mechanisms have been proposed e.g. inhibition of the local production of growth factors, inhibition of growth hormone and somatomedin C, specific binding to tumour cell receptors with subsequent interference of intracellular signals, or inhibition of the effects of oncogene products (cf. Lamberts et al., 1987a; Schally, 1988) . The antiproliferative effect of somatostatin was studied by Mascairdo and Sherline (1982) on two different cell lines and was found to be effective in the range 10--I0 -M, coupled with the physiological inhibition of secretory processes. Previous experiments on cell cultures from an oestrogen-induced, transplantable rat pituitary carcinoma have demonstrated an inhibitory effect of SMS (10-9 M) on both basal and somatomedin C-stimulated secretion of prolactin and on cell proliferation (Lamberts et al., 1986) . Somatostatin was further compared with two analogues in the inhibition of proliferation of a human breast cancer cell line and maximal effects were observed at the 10-9 M concentration.
In the present experiments the DNA contents of human midgut carcinoid tumour cells were studied after 4 days or 2 weeks of incubation with SMS (10O-and 10-0M). Within these periods of time the SMS treatment had caused a pronounced reduction of the media levels of 5-HT without any observable effect on the DNA contents of the tumour cell cultures. In the phase contrast microscope tumour cells treated with SMS could not be distinguished from untreated cells, and the density of tumour cells appeared unchanged. The reduction in 5-HT levels observed during SMS treatment is therefore most likely due to an inhibition of hormone secretion, and possibly reduced hormone synthesis, from the tumour cells rather than unchanged release from a reduced number of tumour cells. In clinical studies on patients with the midgut carcinoid syndrome, using SMS treatment, antiproliferative effects have been reported only in few patients in large series (Soquet et al., 1987; Ahlman et al., 1991; Gorden et al., 1989) in line with the present experimental findings.
